speaker
Operator
Conference Operator

Hello, and welcome to Clover Health's third quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. Ryan, you may begin.

speaker
Ryan Schmidt
Investor Relations

Good afternoon, everyone. Joining me on our call today to discuss the company's third quarter 2026 results are Andrew Toy, Clover Health's chief executive officer, and Clay Thornton, the company's chief financial officer. You can find today's press release and the accompanying supplemental slides, as well as the company's most recent investor deck in the investor events and presentation section of our website at investors.cloverhealth.com. This webcast is being recorded and a replay will be available in the investor relations section of the Clover Health website. I'd also like to caution you that we may make forward-looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the Risk Factors section of our most recent annual report on Form 10-K and other SEC filings. Thank you, Ryan, and welcome everyone to our third quarter earnings call. There is a lot to be excited about at Clover right now. We expect to deliver our first full year of GAAP net income profitability this year.

speaker
Andrew Toy
Chief Executive Officer

Our flagship PPO continues to rank number one in the country on core heatest measures. Early AEP results are reinforcing the strength of our 2027 plan designs. And there is a meaningful 2027 earnings opportunity within our growing base of returning members. All of this builds on a very strong 2026 foundation. Through the first nine months, we've grown membership by nearly 50% year over year, increased consolidated gross profit by over $160 million. More than doubled adjusted EBITDA to $97 million and improved GAAP net income by nearly $100 million, which we believe positions us to be GAAP profitable on a full year basis in 2026, an important milestone for our business. What's most important to me is what is driving our results. At Clover, we bring our health plan, clinically focused AI technology, and financial approach together in one model. Plover Assistant improves care across a broad physician network. Our full risk structure lets us retain the entire upside value as members stay and cohorts mature. And our focused growth strategy lets us scale with discipline. We believe that is why our model is working today and getting stronger as we grow. Now let's shift to discussing stars. We are incredibly proud that our flagship PPO plan achieved five stars for payment year 2028, making it the largest five-star PPO contract in the country. Additionally, our HMO plan achieved four and a half stars, meaning 100% of Clover members are enrolled in plans rated at least four and a half stars for payment year 2028. These star ratings give us continued flexibility to invest in the benefits and affordable access to care that matter most to our members. Underlying this result, our HEDIS quality performance remains industry leading. As we've explained before, this matters because CMS uses HEDIS measures to assess aspects of care quality, including preventative screenings and management of health issues such as diabetes, cancer, and heart disease. And that is why we're proud that for the third year in a row, we ranked number one nationally among comparable PPO plans on core HEDIS measures. At the same time, we have not built Clover around optimizing to STARS ratings. We are built to manage true clinical quality and total cost of care. That distinction matters. Clover Assistant empowers physicians to identify disease earlier and proactively manage chronic conditions. And our full risk model allows us to retain the economic benefit of that care over time. The clinical impact of CA is demonstrated in our published white papers and the financial impact can be seen in our total cost of care. These outcomes reinforce one another. Deeper CA engagement drives better clinical care and strengthens cohort economics over time. Strong stars create more flexibility to invest in member value and support growth and retention. And our full risk approach allows us to retain the resulting improvement in member lifetime value. We believe our 2027 plan designs reflect this compounding advantage. We approach 2027 with a disciplined product strategy centered on physician choice, access to affordable routine care, and sustainable unit economics. Our care model works best when members can engage with their physicians with minimal financial barriers. This is why our plans preserve wide network PPO choice, $0 primary care access, low specialist copays, broad $0 premium options, and some of the lowest Part D deductibles in our markets. We are also seeing the AEP market dynamics that we anticipated now playing out in our markets. There are planned exits, fewer PPO options, and broader benefit repricing, reinforcing the importance of our disciplined approach to plan design. While AEP remains underway, we are not providing formal 2027 guidance, but we feel good about what we are seeing so far. AAP is tracking as expected, and we believe our superior product positioning in our core markets supports another strong year of growth. With high retention and CA-powered cohort maturation, we believe 2027 will be another important step forward. This is distinctively Clover, an AI-powered model where growth, better care, and strong profitable economics compound together in Medicare Advantage. Our 2027 products are designed to extend that advantage as we scale. One of the leading indicators we watch closely is Clover Assistant coverage. The more members we reach through CA, the more opportunity we have to drive better care and stronger economics over time. Importantly, CA coverage has accelerated through the second half of 2026 and is now running ahead of last year's pace. Counterpart takes the same model beyond Clover. Our nation-leading HEDIS performance and strong financial results continue to resonate with partners as we prove out the model in third-party environments. At the same time, we are making strong progress toward our goal of serving as many people through Counterpart as we do through our growing Clover plans. Overall, we are excited about what comes next. I look forward to updating you along the way. Before I turn it over to Clay, who will walk through our third quarter financial performance and improve guidance, I'm pleased to share that our board has appointed him chief financial officer. Clay has been a terrific partner through his time as interim CFO, and I've really enjoyed working alongside him. I've greatly valued his judgment and leadership, and I look forward to continuing our partnership as we build on Clover's progress. Clay, over to you.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API